Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
MONTREAL, July 7, 2015 – Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced the completion of enrollment in its Phase 2 clinical study of THR-184 for the prevention of acute kidney injury (AKI) in “at risk” patients undergoing cardiac surgery. Results from the 452-patient study are expected by January 2016.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.